JP2013509201A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013509201A5 JP2013509201A5 JP2012537194A JP2012537194A JP2013509201A5 JP 2013509201 A5 JP2013509201 A5 JP 2013509201A5 JP 2012537194 A JP2012537194 A JP 2012537194A JP 2012537194 A JP2012537194 A JP 2012537194A JP 2013509201 A5 JP2013509201 A5 JP 2013509201A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- polypeptide
- optionally
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 229920001184 polypeptide Polymers 0.000 claims 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 101710163270 Nuclease Proteins 0.000 claims 15
- 238000006467 substitution reaction Methods 0.000 claims 8
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 7
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 5
- 102000009490 IgG Receptors Human genes 0.000 claims 4
- 108010073807 IgG Receptors Proteins 0.000 claims 4
- 108010083644 Ribonucleases Proteins 0.000 claims 4
- 102000006382 Ribonucleases Human genes 0.000 claims 4
- 102000000989 Complement System Proteins Human genes 0.000 claims 3
- 108010069112 Complement System Proteins Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 101000845618 Homo sapiens Deoxyribonuclease gamma Proteins 0.000 claims 2
- 101000667595 Homo sapiens Ribonuclease pancreatic Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000054371 human DNASE1L3 Human genes 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 108010036169 three prime repair exonuclease 1 Proteins 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000036495 Gastritis atrophic Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 101000863721 Homo sapiens Deoxyribonuclease-1 Proteins 0.000 claims 1
- 208000007466 Male Infertility Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 201000002364 leukopenia Diseases 0.000 claims 1
- 231100001022 leukopenia Toxicity 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- 230000003571 opsonizing effect Effects 0.000 claims 1
- 208000015385 phacoanaphylactic uveitis Diseases 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 206010036601 premature menopause Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25745809P | 2009-11-02 | 2009-11-02 | |
| US61/257,458 | 2009-11-02 | ||
| US37075210P | 2010-08-04 | 2010-08-04 | |
| US61/370,752 | 2010-08-04 | ||
| PCT/US2010/055131 WO2011053982A2 (en) | 2009-11-02 | 2010-11-02 | Therapeutic nuclease compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016045546A Division JP2016174604A (ja) | 2009-11-02 | 2016-03-09 | 治療用ヌクレアーゼ組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013509201A JP2013509201A (ja) | 2013-03-14 |
| JP2013509201A5 true JP2013509201A5 (enExample) | 2013-12-19 |
| JP6199033B2 JP6199033B2 (ja) | 2017-09-20 |
Family
ID=43923071
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537194A Active JP6199033B2 (ja) | 2009-11-02 | 2010-11-02 | 治療用ヌクレアーゼ組成物および方法 |
| JP2016045546A Pending JP2016174604A (ja) | 2009-11-02 | 2016-03-09 | 治療用ヌクレアーゼ組成物および方法 |
| JP2018024633A Active JP7081935B2 (ja) | 2009-11-02 | 2018-02-15 | 治療用ヌクレアーゼ組成物および方法 |
| JP2020127299A Pending JP2021006026A (ja) | 2009-11-02 | 2020-07-28 | 治療用ヌクレアーゼ組成物および方法 |
| JP2020128888A Active JP7237045B2 (ja) | 2009-11-02 | 2020-07-30 | 治療用ヌクレアーゼ組成物および方法 |
| JP2023029040A Active JP7657249B2 (ja) | 2009-11-02 | 2023-02-28 | 治療用ヌクレアーゼ組成物および方法 |
| JP2024228230A Pending JP2025041849A (ja) | 2009-11-02 | 2024-12-25 | 治療用ヌクレアーゼ組成物および方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016045546A Pending JP2016174604A (ja) | 2009-11-02 | 2016-03-09 | 治療用ヌクレアーゼ組成物および方法 |
| JP2018024633A Active JP7081935B2 (ja) | 2009-11-02 | 2018-02-15 | 治療用ヌクレアーゼ組成物および方法 |
| JP2020127299A Pending JP2021006026A (ja) | 2009-11-02 | 2020-07-28 | 治療用ヌクレアーゼ組成物および方法 |
| JP2020128888A Active JP7237045B2 (ja) | 2009-11-02 | 2020-07-30 | 治療用ヌクレアーゼ組成物および方法 |
| JP2023029040A Active JP7657249B2 (ja) | 2009-11-02 | 2023-02-28 | 治療用ヌクレアーゼ組成物および方法 |
| JP2024228230A Pending JP2025041849A (ja) | 2009-11-02 | 2024-12-25 | 治療用ヌクレアーゼ組成物および方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US20130089546A1 (enExample) |
| EP (3) | EP3202898B1 (enExample) |
| JP (7) | JP6199033B2 (enExample) |
| KR (5) | KR102378465B1 (enExample) |
| CN (3) | CN113528485B (enExample) |
| AU (4) | AU2010313103B2 (enExample) |
| BR (1) | BR112012010202A2 (enExample) |
| CA (2) | CA2779615C (enExample) |
| CY (3) | CY1119166T1 (enExample) |
| DK (3) | DK3202898T3 (enExample) |
| ES (2) | ES2626000T3 (enExample) |
| HR (2) | HRP20170757T1 (enExample) |
| HU (2) | HUE032166T2 (enExample) |
| IL (4) | IL297588A (enExample) |
| LT (3) | LT3460056T (enExample) |
| MX (3) | MX341084B (enExample) |
| NZ (1) | NZ813794A (enExample) |
| PL (2) | PL2496691T3 (enExample) |
| PT (2) | PT3202898T (enExample) |
| RS (1) | RS55989B1 (enExample) |
| SG (3) | SG10201912573YA (enExample) |
| SI (3) | SI2496691T1 (enExample) |
| SM (1) | SMT201700248T1 (enExample) |
| WO (1) | WO2011053982A2 (enExample) |
| ZA (3) | ZA201705246B (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011053982A2 (en) | 2009-11-02 | 2011-05-05 | University Of Washington | Therapeutic nuclease compositions and methods |
| JP6063450B2 (ja) | 2011-04-29 | 2017-01-18 | ユニヴァーシティ オブ ワシントン | 治療用ヌクレアーゼ組成物および方法 |
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| FR2983212A1 (fr) * | 2011-11-28 | 2013-05-31 | Lfb Biotechnologies | Aptameres anti-fh, procede pour leur obtention et utilisations |
| US9603907B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Dry powder formulations of dNase I |
| US9353163B2 (en) | 2013-03-14 | 2016-05-31 | Regeneron Pharmaceuticals, Inc. | Apelin fusion proteins and uses thereof |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| HRP20192080T1 (hr) | 2013-10-31 | 2020-02-07 | Resolve Therapeutics, Llc | Terapeutske fuzije nukleaza-albumine i postupci |
| KR20230054509A (ko) | 2013-11-07 | 2023-04-24 | 에디타스 메디신, 인코포레이티드 | 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물 |
| MA39061A1 (fr) | 2013-11-20 | 2017-10-31 | Regeneron Pharma | Modulateurs d'aplnr et leurs utilisations |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| WO2016069889A1 (en) * | 2014-10-31 | 2016-05-06 | Resolve Therapeutics, Llc | Therapeutic nuclease-transferrin fusions and methods |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| DK3478830T3 (da) | 2016-07-01 | 2024-05-21 | Resolve Therapeutics Llc | Optimerede binucleasefusioner og metoder |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| JP6263298B1 (ja) * | 2017-05-09 | 2018-01-17 | 東京瓦斯株式会社 | 検針データの処理システム、その処理プログラム、その処理装置、その処理方法、およびガスメータ |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| IL317968A (en) | 2017-08-18 | 2025-02-01 | Neutrolis Inc | Engineered deoxyribonuclease enzymes and their use in medicine |
| JP7374091B2 (ja) | 2017-08-22 | 2023-11-06 | サナバイオ， エルエルシー | 可溶性インターフェロン受容体およびその使用 |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| KR20250133482A (ko) | 2018-05-11 | 2025-09-05 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3830263A4 (en) | 2018-08-03 | 2022-05-04 | Beam Therapeutics, Inc. | Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence |
| US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| US11058724B2 (en) | 2018-10-08 | 2021-07-13 | Neutrolis, Inc. | Methods of using DNASE1-like 3 in therapy |
| CA3115766A1 (en) | 2018-10-08 | 2020-04-16 | Neutrolis, Inc. | Engineering of dnase enzymes for manufacturing and therapy |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US20220282275A1 (en) | 2018-11-15 | 2022-09-08 | The Broad Institute, Inc. | G-to-t base editors and uses thereof |
| KR20210113261A (ko) | 2019-01-04 | 2021-09-15 | 리졸브 테라퓨틱스, 엘엘씨 | 뉴클레아제 융합 단백질을 사용한 쇼그렌병의 치료 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US11352613B2 (en) | 2019-02-04 | 2022-06-07 | Neutrolis, Inc. | Engineered human extracellular DNASE enzymes |
| WO2020181195A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenine excision |
| WO2020181178A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through thymine alkylation |
| WO2020181202A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to t:a base editing through adenine deamination and oxidation |
| WO2020181180A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to c:g base editors and uses thereof |
| WO2020181193A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenosine methylation |
| DE112020001306T5 (de) | 2019-03-19 | 2022-01-27 | Massachusetts Institute Of Technology | Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2021030666A1 (en) | 2019-08-15 | 2021-02-18 | The Broad Institute, Inc. | Base editing by transglycosylation |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US20230086199A1 (en) | 2019-11-26 | 2023-03-23 | The Broad Institute, Inc. | Systems and methods for evaluating cas9-independent off-target editing of nucleic acids |
| EP4090736A4 (en) * | 2020-01-11 | 2024-02-21 | Yale University | COMPOSITIONS AND METHODS FOR THE TREATMENT, RELIEF AND/OR PREVENTION OF ILLNESSES OR DISORDERS ASSOCIATED WITH DNASE1 AND/OR DNASE1L3 DEFICIENCY |
| US20230235309A1 (en) | 2020-02-05 | 2023-07-27 | The Broad Institute, Inc. | Adenine base editors and uses thereof |
| EP3881862A1 (de) * | 2020-03-18 | 2021-09-22 | Pharis Biotec GmbH | Polypeptid zur therapie von glomerulären nierenerkrankungen und analyse des verlaufes und prognose der abhängigen syndrome |
| US20230159913A1 (en) | 2020-04-28 | 2023-05-25 | The Broad Institute, Inc. | Targeted base editing of the ush2a gene |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| US20230226158A1 (en) * | 2020-06-08 | 2023-07-20 | Yale University | Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections |
| CA3165342A1 (en) | 2020-06-29 | 2022-01-06 | James Arthur Posada | Treatment of sjogren's syndrome with nuclease fusion proteins |
| US12336973B2 (en) | 2020-09-25 | 2025-06-24 | Providence Health & Services—Oregon | Cancer therapeutic compositions and methods targeting DNAse1L3 |
| US12180521B2 (en) * | 2021-02-19 | 2024-12-31 | Theripion, Inc. | Paraoxonase fusion polypeptides and related compositions and methods |
| AU2022224054A1 (en) | 2021-02-19 | 2023-09-28 | Beam Therapeutics Inc. | Recombinant rabies viruses for gene therapy |
| EP4399303A1 (en) | 2021-09-08 | 2024-07-17 | Beam Therapeutics, Inc. | Viral guide rna delivery |
| AU2023325079A1 (en) | 2022-08-16 | 2025-02-13 | President And Fellows Of Harvard College | Evolved cytosine deaminases and methods of editing dna using same |
| EP4652271A1 (en) | 2023-01-18 | 2025-11-26 | The Broad Institute, Inc. | Base editing-mediated readthrough of premature termination codons (bert) |
| WO2025147696A1 (en) | 2024-01-05 | 2025-07-10 | Resolve Therapeutics, Llc | Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents |
| US12416020B2 (en) | 2024-02-20 | 2025-09-16 | Wyvern Pharmaceuticals Inc. | Plasmid encoding a TLR3 and Fc fusion protein |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5453269A (en) * | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5559212A (en) | 1988-04-06 | 1996-09-24 | Alfacell Corporation | Frog embryo and egg-derived tumor cell anti-proliferation protein |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5840840A (en) | 1990-04-17 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Selective RNase cytotoxic reagents |
| WO1992018626A1 (fr) | 1991-04-17 | 1992-10-29 | Laboratoire Europeen De Biotechnologie | POLYPEPTIDES HYDROSOLUBLES AYANT UNE HAUTE AFFINITE POUR LES INTERFERONS α ET $g(b) |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| GB9300686D0 (en) | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
| US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| BR9606706A (pt) * | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| US6482626B2 (en) | 1996-02-05 | 2002-11-19 | Genentech, Inc. | Human DNase |
| US6716974B1 (en) * | 1996-05-31 | 2004-04-06 | Maine Medical Center Research Institute | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| US7247302B1 (en) | 1996-08-02 | 2007-07-24 | Bristol-Myers Squibb Company | Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| CA2269060C (en) | 1996-10-17 | 2009-04-07 | Immunomedics, Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US20030083461A1 (en) | 1997-06-16 | 2003-05-01 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20020192659A1 (en) | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6280991B1 (en) | 1997-10-15 | 2001-08-28 | Wisconsin Alumni Research Foundation | Engineered cytotoxic ribonclease |
| US5840296A (en) | 1997-10-15 | 1998-11-24 | Raines; Ronald T. | Engineered cytotoxic ribonuclease A |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US6239257B1 (en) | 1998-12-30 | 2001-05-29 | Alfacell Corporation | Family of proteins belonging to the pancreatic ribonuclease a superfamily |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| JP2003505020A (ja) | 1999-07-02 | 2003-02-12 | ジェネンテック・インコーポレーテッド | ペプチドリガンドドメイン及び多量体化ドメインを含む融合ペプチド |
| US6175003B1 (en) | 1999-09-10 | 2001-01-16 | Alfacell Corporation | Nucleic acids encoding ribonucleases and methods of making them |
| US7118751B1 (en) | 1999-10-14 | 2006-10-10 | Trubion Pharmaceuticals, Inc. | DNA vaccines encoding antigen linked to a domain that binds CD40 |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| NZ545176A (en) | 2001-01-29 | 2008-05-30 | Biogen Idec Inc | Modified antibodies reactive with CD20 and methods of use |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| BR0207854A (pt) | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
| JP4586310B2 (ja) | 2001-07-04 | 2010-11-24 | 株式会社Ihi | セラミックス複合部材の製造方法 |
| US20060040262A1 (en) * | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7098016B2 (en) | 2002-06-14 | 2006-08-29 | Wisconsin Alumni Research Foundation | Ribonuclease zymogen design |
| JP4459810B2 (ja) | 2002-08-14 | 2010-04-28 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| CA2499816C (en) * | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004041170A2 (en) | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US7067298B2 (en) | 2003-03-31 | 2006-06-27 | Ambion, Inc. | Compositions and methods of using a synthetic Dnase I |
| US7666417B2 (en) * | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
| US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| KR20060124656A (ko) | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질 |
| CA2552788C (en) | 2004-01-12 | 2013-09-24 | Applied Molecular Evolution, Inc. | Fc region variants |
| AU2005214361B2 (en) | 2004-02-13 | 2011-03-24 | Immunomedics, Inc. | Fusion proteins containing recombinant cytotoxic RNAses |
| EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| US8470315B2 (en) | 2004-04-13 | 2013-06-25 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| BRPI0510674A (pt) | 2004-07-15 | 2007-12-26 | Xencor Inc | variantes fc otimizadas |
| CA2578613A1 (en) | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| DE102005009219A1 (de) | 2005-02-25 | 2006-08-31 | Martin-Luther-Universität Halle-Wittenberg | Ribonuclease-Tandemenzyme und Verfahren zu ihrer Herstellung |
| WO2006105062A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| MX2007013924A (es) | 2005-05-09 | 2008-01-28 | Glycart Biotechnology Ag | Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc. |
| EP1896579A2 (en) | 2005-06-16 | 2008-03-12 | Wisconsin Alumni Research Foundation | Cytotoxic ribonuclease variants |
| US7416875B2 (en) | 2005-06-16 | 2008-08-26 | Wisconsin Alumni Research Foundation | Cytotoxic ribonuclease variants |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| HUE026303T2 (hu) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
| JP4860702B2 (ja) | 2005-10-21 | 2012-01-25 | エフ．ホフマン−ラ ロシュ アーゲー | ポリペプチドのリコンビナント発現のための方法 |
| CN101466733A (zh) | 2006-04-14 | 2009-06-24 | 特鲁比昂药品公司 | 包含免疫球蛋白铰链区和Fc效应子功能改变了的Fc区的结合蛋白 |
| ATE547123T1 (de) | 2006-04-21 | 2012-03-15 | Mab Factory Gmbh | Antikörper-rnase-konjugat |
| GB0611444D0 (en) * | 2006-06-09 | 2006-07-19 | Medical Res Council Technology | Rnase H2 complex and genes therefor |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| EP1905841A1 (en) * | 2006-09-25 | 2008-04-02 | Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; | Trex1 as a marker for lupus erythematosus |
| US20080260738A1 (en) | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
| WO2008150485A2 (en) * | 2007-05-29 | 2008-12-11 | Wyeth | Erbb2 binding proteins and use thereof |
| CA2691322A1 (en) | 2007-06-12 | 2008-12-24 | Wyeth | Anti-cd20 therapeutic compositions and methods |
| JP2010532764A (ja) | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
| WO2009015345A1 (en) * | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
| US8067548B2 (en) | 2007-07-26 | 2011-11-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
| EP2220125A4 (en) | 2007-11-13 | 2010-12-29 | Sapphire Energy Inc | PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE |
| AU2009234277B2 (en) | 2008-04-11 | 2014-12-04 | Aptevo Research And Development Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| CA2736373A1 (en) | 2008-09-26 | 2010-04-01 | Timothy W. Behrens | Methods for treating, diagnosing, and monitoring lupus |
| EP2334695B1 (en) | 2008-10-01 | 2015-12-23 | Quintessence Biosciences, Inc. | Therapeutic ribonucleases |
| WO2011053982A2 (en) | 2009-11-02 | 2011-05-05 | University Of Washington | Therapeutic nuclease compositions and methods |
| TWI529163B (zh) | 2011-01-25 | 2016-04-11 | 陶氏農業科學公司 | 用於製備４－胺基－５－氟－３－鹵素－６－（經取代之）吡啶甲酸酯的方法 |
| MX2013009741A (es) | 2011-02-23 | 2014-01-17 | Amgen Inc | Medio de cultivo celular para exposicion a uvc y metodos relacionados al mismo. |
| EP3450563A1 (en) | 2011-02-25 | 2019-03-06 | Recombinetics, Inc. | Genetically modified animals and methods for making the same |
| JP6042871B2 (ja) | 2011-04-21 | 2016-12-14 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｂ型肝炎ウイルス（ｈｂｖ）発現の調節 |
| JP6063450B2 (ja) | 2011-04-29 | 2017-01-18 | ユニヴァーシティ オブ ワシントン | 治療用ヌクレアーゼ組成物および方法 |
| US20140178479A1 (en) | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| US9401875B2 (en) | 2012-06-01 | 2016-07-26 | Nippon Telegraph And Telephone Corporation | Packet transfer processing method and packet transfer processing device |
| HRP20192080T1 (hr) | 2013-10-31 | 2020-02-07 | Resolve Therapeutics, Llc | Terapeutske fuzije nukleaza-albumine i postupci |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| DK3478830T3 (da) | 2016-07-01 | 2024-05-21 | Resolve Therapeutics Llc | Optimerede binucleasefusioner og metoder |
| JP6349003B1 (ja) | 2017-03-17 | 2018-06-27 | 東洋ビーネット株式会社 | 耐熱性ルシフェラーゼ |
-
2010
- 2010-11-02 WO PCT/US2010/055131 patent/WO2011053982A2/en not_active Ceased
- 2010-11-02 HR HRP20170757TT patent/HRP20170757T1/hr unknown
- 2010-11-02 KR KR1020207015149A patent/KR102378465B1/ko active Active
- 2010-11-02 ES ES10827655.1T patent/ES2626000T3/es active Active
- 2010-11-02 DK DK16198956.1T patent/DK3202898T3/en active
- 2010-11-02 KR KR1020187037619A patent/KR102118584B1/ko active Active
- 2010-11-02 EP EP16198956.1A patent/EP3202898B1/en active Active
- 2010-11-02 CA CA2779615A patent/CA2779615C/en active Active
- 2010-11-02 HU HUE10827655A patent/HUE032166T2/en unknown
- 2010-11-02 CN CN202110852975.7A patent/CN113528485B/zh active Active
- 2010-11-02 MX MX2012005062A patent/MX341084B/es active IP Right Grant
- 2010-11-02 BR BR112012010202A patent/BR112012010202A2/pt active Search and Examination
- 2010-11-02 SG SG10201912573YA patent/SG10201912573YA/en unknown
- 2010-11-02 LT LTEP18190143.0T patent/LT3460056T/lt unknown
- 2010-11-02 AU AU2010313103A patent/AU2010313103B2/en active Active
- 2010-11-02 CN CN201610979041.9A patent/CN106399276B/zh active Active
- 2010-11-02 KR KR1020127014363A patent/KR101934923B1/ko active Active
- 2010-11-02 SG SG10201912571XA patent/SG10201912571XA/en unknown
- 2010-11-02 EP EP10827655.1A patent/EP2496691B1/en active Active
- 2010-11-02 SI SI201031462A patent/SI2496691T1/sl unknown
- 2010-11-02 DK DK18190143.0T patent/DK3460056T3/da active
- 2010-11-02 CA CA3091939A patent/CA3091939A1/en active Pending
- 2010-11-02 PL PL10827655T patent/PL2496691T3/pl unknown
- 2010-11-02 SI SI201032038T patent/SI3460056T1/sl unknown
- 2010-11-02 LT LTEP10827655.1T patent/LT2496691T/lt unknown
- 2010-11-02 RS RS20170510A patent/RS55989B1/sr unknown
- 2010-11-02 SM SM20170248T patent/SMT201700248T1/it unknown
- 2010-11-02 KR KR1020247000800A patent/KR20240007725A/ko not_active Ceased
- 2010-11-02 MX MX2014013439A patent/MX360465B/es unknown
- 2010-11-02 DK DK10827655.1T patent/DK2496691T3/en active
- 2010-11-02 SI SI201031820T patent/SI3202898T1/sl unknown
- 2010-11-02 PL PL16198956T patent/PL3202898T3/pl unknown
- 2010-11-02 KR KR1020227009207A patent/KR102624939B1/ko active Active
- 2010-11-02 PT PT16198956T patent/PT3202898T/pt unknown
- 2010-11-02 SG SG10201406801XA patent/SG10201406801XA/en unknown
- 2010-11-02 PT PT108276551T patent/PT2496691T/pt unknown
- 2010-11-02 US US13/505,421 patent/US20130089546A1/en not_active Abandoned
- 2010-11-02 NZ NZ813794A patent/NZ813794A/en unknown
- 2010-11-02 CN CN201080060471.1A patent/CN102770533B/zh active Active
- 2010-11-02 LT LTEP16198956.1T patent/LT3202898T/lt unknown
- 2010-11-02 JP JP2012537194A patent/JP6199033B2/ja active Active
- 2010-11-02 ES ES16198956T patent/ES2702053T3/es active Active
- 2010-11-02 EP EP18190143.0A patent/EP3460056B1/en active Active
- 2010-11-02 IL IL297588A patent/IL297588A/en unknown
- 2010-11-02 HU HUE16198956A patent/HUE041426T2/hu unknown
-
2011
- 2011-08-03 US US13/197,731 patent/US8841416B2/en active Active
-
2012
- 2012-04-29 IL IL219475A patent/IL219475A0/en active IP Right Grant
- 2012-04-30 MX MX2018013333A patent/MX2018013333A/es unknown
-
2013
- 2013-03-12 US US13/796,730 patent/US20130177561A1/en not_active Abandoned
- 2013-03-13 US US13/799,854 patent/US20130183308A1/en not_active Abandoned
- 2013-03-13 US US13/799,843 patent/US20130184334A1/en not_active Abandoned
-
2014
- 2014-04-22 US US14/258,319 patent/US20140227269A1/en not_active Abandoned
- 2014-10-16 US US14/516,161 patent/US9790479B2/en active Active
-
2016
- 2016-03-09 JP JP2016045546A patent/JP2016174604A/ja active Pending
- 2016-04-06 AU AU2016202135A patent/AU2016202135B2/en active Active
-
2017
- 2017-05-22 CY CY20171100532T patent/CY1119166T1/el unknown
- 2017-08-03 ZA ZA2017/05246A patent/ZA201705246B/en unknown
- 2017-08-17 US US15/679,746 patent/US11306297B2/en active Active
-
2018
- 2018-02-14 AU AU2018201071A patent/AU2018201071B2/en active Active
- 2018-02-15 JP JP2018024633A patent/JP7081935B2/ja active Active
- 2018-09-05 ZA ZA201805962A patent/ZA201805962B/en unknown
- 2018-11-21 IL IL263180A patent/IL263180B/en active IP Right Grant
- 2018-12-12 HR HRP20182102TT patent/HRP20182102T1/hr unknown
- 2018-12-21 CY CY20181101388T patent/CY1121220T1/el unknown
-
2020
- 2020-04-22 AU AU2020202688A patent/AU2020202688B2/en active Active
- 2020-04-28 IL IL274309A patent/IL274309B2/en unknown
- 2020-07-28 JP JP2020127299A patent/JP2021006026A/ja active Pending
- 2020-07-30 JP JP2020128888A patent/JP7237045B2/ja active Active
- 2020-08-21 ZA ZA2020/05216A patent/ZA202005216B/en unknown
- 2020-11-03 CY CY20201101036T patent/CY1123684T1/el unknown
-
2022
- 2022-03-16 US US17/696,364 patent/US12435322B2/en active Active
-
2023
- 2023-02-28 JP JP2023029040A patent/JP7657249B2/ja active Active
-
2024
- 2024-12-25 JP JP2024228230A patent/JP2025041849A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013509201A5 (enExample) | ||
| JP2014519809A5 (enExample) | ||
| US12152060B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| US20230355728A1 (en) | Peptidic chimeric antigen receptor t cell switches and uses thereof | |
| HRP20170757T1 (hr) | Terapeutski pripravci nukleaze i postupci | |
| JP2021007390A5 (enExample) | ||
| JP2020203926A5 (enExample) | ||
| TWI838621B (zh) | 具有經修飾重鏈恆定區之多特異性重鏈抗體 | |
| IL300276A (en) | Therapeutic nuclease compositions and methods | |
| EP3201231B1 (en) | Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28 | |
| KR20170074852A (ko) | 대사 장애를 치료하기 위한 조성물 및 사용 방법 | |
| JP2019530430A5 (enExample) | ||
| JP7702445B2 (ja) | 免疫調節融合タンパク質 | |
| WO2008138017A2 (en) | Methods and compositions for modifying t cell immune responses and inflammation | |
| JP2022529059A (ja) | バリアントｉｃｏｓリガンド（ｉｃｏｓｌ）融合タンパク質の方法および使用 | |
| JP2024503506A (ja) | インターロイキン－２変異体およびその使用 | |
| KR20140135766A (ko) | 종양괴사인자 수용체 융합 단백질 및 이를 이용하는 방법 | |
| WO2022050401A2 (en) | Interleukin-2 muteins and uses thereof | |
| HRP20201752T1 (hr) | Terapeutski pripravci nukleaze i postupci | |
| WO2008003748A2 (en) | Cd300lg polypeptides and their use in treating autoimmune diseases | |
| Patel | Enhancing the half-life of Interleukin 2 by conjugation to the Transthyretin Ligand, TLHE And Enhancing the efficacy of peptides that inhibit COVID 19 viral entry | |
| JPWO2022117068A5 (enExample) | ||
| NZ753689A (en) | Therapeutic nuclease compositions and methods | |
| NZ774435B2 (en) | Therapeutic nuclease compositions and methods | |
| HK40093172A (en) | Multispecific heavy chain antibodies with modified heavy chain constant regions |